<p>Farther Finance Advisors LLC 在最近向证券交易委员会（SEC）提交的文件中表示，在第二季度其对雅培（NYSE:ABT - 免费报告）的持股增加了 19.7%。该机构投资者在此期间购买了 6,486 股后，持有 39,491 股该医疗产品制造商的股票。Farther Finance Advisors LLC 在雅培的持股在最近一个季度末的价值为 5,371,000 美元。</p>
<p>获取 <strong>雅培</strong> 的提醒：</p>
<ul>
<li>为什么雅培在 2025 年第二季度是一个买入机会：增长与收益</li>
</ul>
<p>其他大型投资者也买卖了该公司的股票。Hughes Financial Services LLC 在第一季度获得了雅培的新股份，估值约为 27,000 美元。Abound Financial LLC 在第一季度购买了雅培的新股份，价值 28,000 美元。Elequin Capital LP 在第一季度获得了雅培的新职位，价值 30,000 美元。Wormser Freres Gestion 在第四季度获得了雅培的新股份，估值为 32,000 美元。最后，JCIC Asset Management Inc. 在第一季度购买了雅培的新股份，价值约 32,000 美元。75.18% 的股票由机构投资者持有。</p>
<h2>雅培股票上涨 1.2%</h2>
<p>周五，ABT 股票开盘价为 136.22 美元。雅培的 52 周低点为 110.86 美元，52 周高点为 141.23 美元。该股票的 50 日移动平均线为 130.47 美元，200 日移动平均线为 131.14 美元。公司的债务与股本比率为 0.25，速动比率为 1.30，流动比率为 1.82。公司的市值为 2370.9 亿美元，市盈率为 17.07，PEG 比率为 2.58，贝塔值为 0.69。</p>
<ul>
<li>如果你想购买 AbbVie 但没有，现在仍然有机会购买</li>
</ul>
<p>雅培（NYSE:ABT - 获取免费报告）最近于 7 月 17 日星期四发布了季度财报。该医疗产品制造商报告的季度每股收益为 1.26 美元，符合分析师的共识预期 1.26 美元。该公司在本季度的收入为 111.4 亿美元，而分析师预期为 110.1 亿美元。雅培的净利润率为 32.43%，股本回报率为 18.32%。该公司的季度收入同比增长 7.4%。在去年同期，该公司每股收益为 1.14 美元。雅培已将其 2025 财年的指导目标设定为 5.100-5.200 每股收益。2025 年第三季度的指导目标为 1.280-1.320 每股收益。整体来看，股票研究分析师预测雅培在当前年度的每股收益为 5.14。</p>
<h2>雅培宣布分红</h2>
<p>该公司最近还宣布了一项季度分红，将于 11 月 17 日星期一支付。10 月 15 日星期三的登记投资者将获得每股 0.59 美元的分红。除息日为 10 月 15 日星期三。这代表着每年 2.36 美元的分红和 1.7% 的分红收益率。雅培的派息比率目前为 29.57%。</p>
<h2>华尔街分析师观点</h2>
<ul>
<li>抗关税的雅培有望创下新高</li>
</ul>
<p>一些分析师最近对 ABT 股票发布了报告。加拿大皇家银行将雅培的目标价格从 145.00 美元上调至 147.00 美元，并在 7 月 15 日的研究报告中给予该公司 “跑赢大盘” 的评级。Evercore ISI 将雅培的目标价格从 140.00 美元上调至 145.00 美元，并在 7 月 8 日的研究报告中给予该股票 “跑赢大盘” 的评级。Leerink Partners 在 6 月 16 日的研究报告中开始覆盖雅培股票。他们给予该公司 “市场表现” 的评级，目标价格为 143.00 美元。Raymond James Financial 将雅培股票的目标价格从 142.00 美元下调至 141.00 美元，并在 7 月 18 日的研究报告中对该股票设定了 “跑赢大盘” 的评级。最后，William Blair 在 7 月 17 日的研究报告中将雅培股票的评级提升至 “强力买入”。两位分析师给予该股票 “强力买入” 评级，十五位给予 “买入” 评级，四位给予 “持有” 评级。根据 MarketBeat 的数据，该股票的共识评级为 “适度买入”，平均目标价格为 145.22 美元。</p>
<p><strong>获取我们关于 ABT 的最新报告</strong></p>
<h2>内部活动</h2>
<p>在其他消息中，首席财务官 Philip P. Boudreau 于 8 月 8 日星期五出售了 5,550 股公司的股票。股票以 134.55 美元的平均价格出售，总交易额为 746,752.50 美元。出售后，首席财务官在公司持有 51,003 股，价值约为 6,862,453.65 美元。此次交易使其持股减少了 9.81%。该交易已在向 SEC 的文件中披露，SEC 网站上可以访问。公司内部人士持有该公司股票的 0.46%。</p>
<h2>雅培公司简介</h2>
<p>（免费报告）</p>
<p>雅培及其子公司在全球范围内发现、开发、制造和销售医疗保健产品。它分为四个部门：成熟药品、诊断产品、营养产品和医疗器械。该公司提供用于治疗胰腺外分泌功能不足、肠易激综合症或胆道痉挛、肝内胆汁淤积或抑郁症状、妇科疾病、激素替代疗法、血脂异常、高血压、甲状腺功能减退、梅尼埃病和前庭眩晕、疼痛、发热、炎症和偏头痛的仿制药，以及提供抗感染药物克拉霉素、流感疫苗和调节结肠生理节律的产品。</p>
<h2>相关文章</h2>
<ul>
<li>我们更看好的五只股票，而不是雅培</li>
<li>交通运输股票投资</li>
<li>卡特彼勒股票创下历史新高——还有上涨空间吗？</li>
<li>什么是股息冠军？如何投资于冠军股票</li>
<li>伯克希尔支持的 Lennar 在第三季度业绩疲软后下滑</li>
<li>什么是认沽期权成交量？</li>
<li>分析师对好时转为看涨——百事可乐是下一个价值投资吗？</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCVA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCVA"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1000 美元在雅培吗？</h2>
<p>在考虑雅培之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而雅培并不在名单上。</p>
<p>虽然雅培目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

雅培

<p>Farther Finance Advisors LLC 在第二季度将其在雅培（NYSE:ABT）的持股增加了 19.7%，目前拥有 39,491 股，价值 537 万美元。该公司报告的季度每股收益为 1.26 美元，符合预期，收入为 111.4 亿美元。雅培宣布每股季度股息为 0.59 美元，收益率为 1.7%。分析师对雅培的共识评级为 “适度买入”，平均目标价为 145.22 美元。首席财务官 Philip P. Boudreau 最近出售了 5,550 股</p>

<p>Farther Finance Advisors LLC increased its holdings in shares of Abbott Laboratories (NYSE:ABT - Free Report) by 19.7% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 39,491 shares of the healthcare product maker's stock after purchasing an additional 6,486 shares during the period. Farther Finance Advisors LLC's holdings in Abbott Laboratories were worth $5,371,000 at the end of the most recent quarter.</p>
<div class="lb-trans"><p>Farther Finance Advisors LLC 在最近向证券交易委员会（SEC）提交的文件中表示，在第二季度其对雅培（NYSE:ABT - 免费报告）的持股增加了 19.7%。该机构投资者在此期间购买了 6,486 股后，持有 39,491 股该医疗产品制造商的股票。Farther Finance Advisors LLC 在雅培的持股在最近一个季度末的价值为 5,371,000 美元。</p>
</div><p>Get <strong>Abbott Laboratories</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>雅培</strong> 的提醒：</p>
</div><ul>
<li>Why Abbott Laboratories Is a Q2 2025 Buy: Growth &amp; Yield</li>
</ul>
<div class="lb-trans"><ul>
<li>为什么雅培在 2025 年第二季度是一个买入机会：增长与收益</li>
</ul>
</div><p>Other large investors have also bought and sold shares of the company. Hughes Financial Services LLC acquired a new stake in Abbott Laboratories in the 1st quarter valued at approximately $27,000. Abound Financial LLC bought a new stake in shares of Abbott Laboratories in the first quarter worth $28,000. Elequin Capital LP acquired a new position in Abbott Laboratories during the first quarter worth $30,000. Wormser Freres Gestion acquired a new stake in Abbott Laboratories in the 4th quarter valued at $32,000. Finally, JCIC Asset Management Inc. bought a new stake in Abbott Laboratories during the 1st quarter worth about $32,000. 75.18% of the stock is owned by institutional investors.</p>
<div class="lb-trans"><p>其他大型投资者也买卖了该公司的股票。Hughes Financial Services LLC 在第一季度获得了雅培的新股份，估值约为 27,000 美元。Abound Financial LLC 在第一季度购买了雅培的新股份，价值 28,000 美元。Elequin Capital LP 在第一季度获得了雅培的新职位，价值 30,000 美元。Wormser Freres Gestion 在第四季度获得了雅培的新股份，估值为 32,000 美元。最后，JCIC Asset Management Inc. 在第一季度购买了雅培的新股份，价值约 32,000 美元。75.18% 的股票由机构投资者持有。</p>
</div><h2>Abbott Laboratories Stock Up 1.2%</h2>
<div class="lb-trans"><h2>雅培股票上涨 1.2%</h2>
</div><p>ABT stock opened at $136.22 on Friday. Abbott Laboratories has a fifty-two week low of $110.86 and a fifty-two week high of $141.23. The stock has a fifty day moving average of $130.47 and a 200-day moving average of $131.14. The company has a debt-to-equity ratio of 0.25, a quick ratio of 1.30 and a current ratio of 1.82. The company has a market capitalization of $237.09 billion, a price-to-earnings ratio of 17.07, a PEG ratio of 2.58 and a beta of 0.69.</p>
<div class="lb-trans"><p>周五，ABT 股票开盘价为 136.22 美元。雅培的 52 周低点为 110.86 美元，52 周高点为 141.23 美元。该股票的 50 日移动平均线为 130.47 美元，200 日移动平均线为 131.14 美元。公司的债务与股本比率为 0.25，速动比率为 1.30，流动比率为 1.82。公司的市值为 2370.9 亿美元，市盈率为 17.07，PEG 比率为 2.58，贝塔值为 0.69。</p>
</div><ul>
<li>If You Wanted To Buy AbbVie and Didn’t, There’s Still Time To Buy</li>
</ul>
<div class="lb-trans"><ul>
<li>如果你想购买 AbbVie 但没有，现在仍然有机会购买</li>
</ul>
</div><p>Abbott Laboratories (NYSE:ABT - Get Free Report) last released its quarterly earnings results on Thursday, July 17th. The healthcare product maker reported $1.26 EPS for the quarter, meeting analysts' consensus estimates of $1.26. The firm had revenue of $11.14 billion during the quarter, compared to analyst estimates of $11.01 billion. Abbott Laboratories had a net margin of 32.43% and a return on equity of 18.32%. The business's revenue for the quarter was up 7.4% on a year-over-year basis. During the same period in the previous year, the business earned $1.14 EPS. Abbott Laboratories has set its FY 2025 guidance at 5.100-5.200 EPS. Q3 2025 guidance at 1.280-1.320 EPS. As a group, equities research analysts predict that Abbott Laboratories will post 5.14 earnings per share for the current year.</p>
<div class="lb-trans"><p>雅培（NYSE:ABT - 获取免费报告）最近于 7 月 17 日星期四发布了季度财报。该医疗产品制造商报告的季度每股收益为 1.26 美元，符合分析师的共识预期 1.26 美元。该公司在本季度的收入为 111.4 亿美元，而分析师预期为 110.1 亿美元。雅培的净利润率为 32.43%，股本回报率为 18.32%。该公司的季度收入同比增长 7.4%。在去年同期，该公司每股收益为 1.14 美元。雅培已将其 2025 财年的指导目标设定为 5.100-5.200 每股收益。2025 年第三季度的指导目标为 1.280-1.320 每股收益。整体来看，股票研究分析师预测雅培在当前年度的每股收益为 5.14。</p>
</div><h2>Abbott Laboratories Announces Dividend</h2>
<div class="lb-trans"><h2>雅培宣布分红</h2>
</div><p>The business also recently declared a quarterly dividend, which will be paid on Monday, November 17th. Investors of record on Wednesday, October 15th will be given a dividend of $0.59 per share. The ex-dividend date is Wednesday, October 15th. This represents a $2.36 annualized dividend and a dividend yield of 1.7%. Abbott Laboratories's payout ratio is currently 29.57%.</p>
<div class="lb-trans"><p>该公司最近还宣布了一项季度分红，将于 11 月 17 日星期一支付。10 月 15 日星期三的登记投资者将获得每股 0.59 美元的分红。除息日为 10 月 15 日星期三。这代表着每年 2.36 美元的分红和 1.7% 的分红收益率。雅培的派息比率目前为 29.57%。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>华尔街分析师观点</h2>
</div><ul>
<li>Tariff-Resistant Abbott Laboratories on Track for New Highs</li>
</ul>
<div class="lb-trans"><ul>
<li>抗关税的雅培有望创下新高</li>
</ul>
</div><p>A number of analysts recently issued reports on ABT shares. Royal Bank Of Canada lifted their target price on Abbott Laboratories from $145.00 to $147.00 and gave the company an &#34;outperform&#34; rating in a research report on Tuesday, July 15th. Evercore ISI upped their price objective on Abbott Laboratories from $140.00 to $145.00 and gave the stock an &#34;outperform&#34; rating in a research note on Tuesday, July 8th. Leerink Partners initiated coverage on shares of Abbott Laboratories in a research note on Monday, June 16th. They issued a &#34;market perform&#34; rating and a $143.00 target price for the company. Raymond James Financial dropped their price target on shares of Abbott Laboratories from $142.00 to $141.00 and set an &#34;outperform&#34; rating on the stock in a research report on Friday, July 18th. Finally, William Blair raised shares of Abbott Laboratories to a &#34;strong-buy&#34; rating in a research report on Thursday, July 17th. Two analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat, the stock has a consensus rating of &#34;Moderate Buy&#34; and an average price target of $145.22.</p>
<div class="lb-trans"><p>一些分析师最近对 ABT 股票发布了报告。加拿大皇家银行将雅培的目标价格从 145.00 美元上调至 147.00 美元，并在 7 月 15 日的研究报告中给予该公司 “跑赢大盘” 的评级。Evercore ISI 将雅培的目标价格从 140.00 美元上调至 145.00 美元，并在 7 月 8 日的研究报告中给予该股票 “跑赢大盘” 的评级。Leerink Partners 在 6 月 16 日的研究报告中开始覆盖雅培股票。他们给予该公司 “市场表现” 的评级，目标价格为 143.00 美元。Raymond James Financial 将雅培股票的目标价格从 142.00 美元下调至 141.00 美元，并在 7 月 18 日的研究报告中对该股票设定了 “跑赢大盘” 的评级。最后，William Blair 在 7 月 17 日的研究报告中将雅培股票的评级提升至 “强力买入”。两位分析师给予该股票 “强力买入” 评级，十五位给予 “买入” 评级，四位给予 “持有” 评级。根据 MarketBeat 的数据，该股票的共识评级为 “适度买入”，平均目标价格为 145.22 美元。</p>
</div><p><strong>Get Our Latest Report on ABT</strong></p>
<div class="lb-trans"><p><strong>获取我们关于 ABT 的最新报告</strong></p>
</div><h2>Insider Activity</h2>
<div class="lb-trans"><h2>内部活动</h2>
</div><p>In other news, CFO Philip P. Boudreau sold 5,550 shares of the business's stock in a transaction on Friday, August 8th. The shares were sold at an average price of $134.55, for a total transaction of $746,752.50. Following the sale, the chief financial officer owned 51,003 shares in the company, valued at approximately $6,862,453.65. The trade was a 9.81% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Corporate insiders own 0.46% of the company's stock.</p>
<div class="lb-trans"><p>在其他消息中，首席财务官 Philip P. Boudreau 于 8 月 8 日星期五出售了 5,550 股公司的股票。股票以 134.55 美元的平均价格出售，总交易额为 746,752.50 美元。出售后，首席财务官在公司持有 51,003 股，价值约为 6,862,453.65 美元。此次交易使其持股减少了 9.81%。该交易已在向 SEC 的文件中披露，SEC 网站上可以访问。公司内部人士持有该公司股票的 0.46%。</p>
</div><h2>Abbott Laboratories Profile</h2>
<div class="lb-trans"><h2>雅培公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.</p>
<div class="lb-trans"><p>雅培及其子公司在全球范围内发现、开发、制造和销售医疗保健产品。它分为四个部门：成熟药品、诊断产品、营养产品和医疗器械。该公司提供用于治疗胰腺外分泌功能不足、肠易激综合症或胆道痉挛、肝内胆汁淤积或抑郁症状、妇科疾病、激素替代疗法、血脂异常、高血压、甲状腺功能减退、梅尼埃病和前庭眩晕、疼痛、发热、炎症和偏头痛的仿制药，以及提供抗感染药物克拉霉素、流感疫苗和调节结肠生理节律的产品。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>相关文章</h2>
</div><ul>
<li>Five stocks we like better than Abbott Laboratories</li>
<li>Transportation Stocks Investing</li>
<li>Caterpillar Stock Hits All-Time High—Is There More Room to Run?</li>
<li>What Are Dividend Champions? How to Invest in the Champions</li>
<li>Berkshire-Backed Lennar Slides After Weak Q3 Earnings</li>
<li>What is Put Option Volume?</li>
<li>Analysts Turn Bullish on Hershey—Is Pepsi the Next Value Play?</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，而不是雅培</li>
<li>交通运输股票投资</li>
<li>卡特彼勒股票创下历史新高——还有上涨空间吗？</li>
<li>什么是股息冠军？如何投资于冠军股票</li>
<li>伯克希尔支持的 Lennar 在第三季度业绩疲软后下滑</li>
<li>什么是认沽期权成交量？</li>
<li>分析师对好时转为看涨——百事可乐是下一个价值投资吗？</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCVA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=ABT"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Abbott Laboratories Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在雅培吗？</h2>
</div><p>Before you consider Abbott Laboratories, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑雅培之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Abbott Laboratories wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而雅培并不在名单上。</p>
</div><p>While Abbott Laboratories currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然雅培目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Farther Finance Advisors LLC 持有雅培公司价值 537 万美元的股权